<DOC>
	<DOCNO>NCT02451228</DOCNO>
	<brief_summary>This study follow pregnant woman take indomethacin preterm labor find pharmacokinetics ( body drug ) pharmacodynamics ( effectiveness drug treat specific intended disease process ) medication . This help u develop information medication dose specific pregnant woman experience preterm labor . Indomethacin often prescribe pregnant woman present preterm labor shorten cervix , place risk preterm labor delivery . Indomethacin use since 1970s prolong pregnancy decrease uterine contraction . However , despite widespread use indomethacin pregnancy , limited information available help physician determine much indomethacin prescribe often prescribe .</brief_summary>
	<brief_title>Indomethacin PK PD Therapy Pregnancy</brief_title>
	<detailed_description>Determine pharmacokinetics , pharmacodynamics pharmacogenomics Indomethacin pregnant patient hypothesis estradiol level pregnancy ( 12-32 week gestation ) CYP2C9 polymorphisms affect PK indomethacin , subsequently , response indomethacin therapy patient risk PTB . This hypothesis test follow specific aim : ( 1 ) Determine PK indomethacin pregnant woman risk PTB PD effect reduce rate PTB 34 week gestation , well association PK secondary maternal/neonatal clinical outcome ; ( 2 ) Determine effect maternal level estradiol mid-pregnancy CYP2C9 polymorphisms indomethacin biotransformation O-desmethylindomethacin pregnant patient ; ( 3 ) Construct population PK/PD model indomethacin patient risk PTB ( 12-32 week gestation ) order optimize dose dosing frequency indomethacin prescribe individual base covariates race/ethnicity , CYP2C9 genotype , gestational age , estradiol level , smoke status , body mass index ( BMI ) . The investigator enroll 300 subject sPTL shorten cervix prospective opportunistic PK study design correlate PK indomethacin , patient genotype , clinical outcome . The investigator merge dose , sample , demographic , clinical information drug concentration data use population PK methodology analyze data use nonlinear mixed effect model . Quantification difference within individual allows identification covariates ( e.g. , CYP2C9 genotype , estradiol level , BMI , etc . ) explain variability affect drug exposure . These covariates , significant , used future optimize dose individual patient risk PTB . Achieving goal individualize indomethacin therapy could significant impact clinical practice improve maternal neonatal outcome .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Obstetric Labor , Premature</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>To enrol study , patient must meet following criterion : 1 . Age least 18 year 2 . Singleton gestation 3 . 12 0/7 32 0/7 week gestation ( see Gestational Age Determination section 3.2.1.1 ) 4 . Patient receive indomethacin follow diagnosis : 1 . Preterm labor : regular uterine contraction document cervical change dilatation â‰¥ 2 cm 80 % effacement 2 . Cervical shortening ( &lt; 2.5 cm document transvaginal ultrasound ) without funnel membrane 5 . Maternal fetal condition allows anticipate delay delivery 24 hour Exclusion criterion include : 1 . Contraindications indomethacin use ( history maternal bleeding disorder , thrombocytopenia , maternal hepatic , gastrointestinal ulcerative , renal dysfunction , asthma ) 2 . Known fetal abnormality , genetic syndrome , intrauterine fetal demise 3 . Anticipated delivery le 24 hour , cervical dilatation &gt; 6 cm 4 . Preterm premature rupture membrane 5 . Suspected chorioamnionitis 6 . Multifetal gestation 7 . Oligohydramnios ( DVP &lt; 2 cm ) 8 . Congenital Uterine anomaly 9 . Indomethacin use fibroid degeneration polyhydramnios subject indomethacin another medical condition 10 . Vaginal bleeding : suspect placental abruption , placenta previa 11 . Planned preterm delivery maternal/fetal indication 12 . Nonreassuring fetal status 13 . Planned delivery outside UTMB participation another intervention trial may affect maternal neonatal outcomes 14 . Unsure gestational age due possibility intrauterine growth restriction 15 . Hematocrit &lt; 28 % ( determine recent result within 1 month enrollment ) 16 . Prisoners</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Preterm labor</keyword>
	<keyword>Preterm birth</keyword>
	<keyword>Estradiol</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Short Cervix</keyword>
	<keyword>CYP2C9 Genotype</keyword>
</DOC>